There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dr Reddy’s Laboratories (RDY – Research Report) and Dexcom (DXCM – Research Report) with bullish sentiments.
Dr Reddy’s Laboratories (RDY)
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories, with a price target of $70.00. The company’s shares closed last Wednesday at $55.19.
According to TipRanks.com, Prasad is a 2-star analyst with an average return of 0.3% and a 40.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Amneal Pharmaceuticals, and Jazz Pharmaceuticals.
Dr Reddy’s Laboratories has an analyst consensus of Moderate Buy, with a price target consensus of $67.00.
See the top stocks recommended by analysts >>
Dexcom (DXCM)
BTIG analyst Marie Thibault reiterated a Buy rating on Dexcom today and set a price target of $134.00. The company’s shares closed last Wednesday at $117.26, close to its 52-week high of $126.44.
According to TipRanks.com, Thibault is a 3-star analyst with an average return of 2.7% and a 36.4% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Edwards Lifesciences, and Senseonics Holdings.
Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $140.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RDY: